- Home
- AQST
as of 12-02-2025 3:58pm EST
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | WARREN |
| Market Cap: | 809.3M | IPO Year: | 2018 |
| Target Price: | $10.00 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.12 - $7.55 | Next Earning Date: | 11-05-2025 |
| Revenue: | $43,397,000 | Revenue Growth: | -26.32% |
| Revenue Growth (this year): | -20.29% | Revenue Growth (next year): | 51.39% |
AI-Powered AQST Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Aquestive Therapeutics Inc. (AQST)
See Remarks
Avg Cost/Share
$7.00
Shares
10,000
Total Value
$70,000.00
Owned After
268,323
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$7.00
Shares
20,272
Total Value
$141,904.00
Owned After
282,475
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$7.01
Shares
67,575
Total Value
$473,700.75
Owned After
240,771
SEC Form 4
President and CEO
Avg Cost/Share
$6.03
Shares
91,343
Total Value
$551,191.06
Owned After
923,430
SEC Form 4
See Remarks
Avg Cost/Share
$6.30
Shares
10,000
Total Value
$63,000.00
Owned After
268,323
SEC Form 4
President and CEO
Avg Cost/Share
$6.00
Shares
400
Total Value
$2,400.00
Owned After
923,430
SEC Form 4
See Remarks
Avg Cost/Share
$5.30
Shares
15,000
Total Value
$79,500.00
Owned After
268,323
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$5.00
Shares
62,180
Total Value
$310,900.00
Owned After
240,771
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Boyd Peter E. | AQST | See Remarks | Oct 15, 2025 | Sell | $7.00 | 10,000 | $70,000.00 | 268,323 | |
| Kraus Carl N | AQST | Chief Medical Officer | Oct 15, 2025 | Sell | $7.00 | 20,272 | $141,904.00 | 282,475 | |
| Jung Cassie | AQST | Chief Operating Officer | Oct 15, 2025 | Sell | $7.01 | 67,575 | $473,700.75 | 240,771 | |
| Barber Daniel | AQST | President and CEO | Sep 26, 2025 | Sell | $6.03 | 91,343 | $551,191.06 | 923,430 | |
| Boyd Peter E. | AQST | See Remarks | Sep 26, 2025 | Sell | $6.30 | 10,000 | $63,000.00 | 268,323 | |
| Barber Daniel | AQST | President and CEO | Sep 19, 2025 | Sell | $6.00 | 400 | $2,400.00 | 923,430 | |
| Boyd Peter E. | AQST | See Remarks | Sep 5, 2025 | Sell | $5.30 | 15,000 | $79,500.00 | 268,323 | |
| Jung Cassie | AQST | Chief Operating Officer | Sep 4, 2025 | Sell | $5.00 | 62,180 | $310,900.00 | 240,771 |
Compare AQST vs Leading Stocks
See how AQST stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AQST Aquestive Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.